Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Dominic J Allocco , Mary V Jacoski , Barbara Huibregtse , et al Added: 3 years ago
Advances in drug-eluting stent technology have continued to improve clinical outcomes for patients undergoing percutaneous coronary intervention (PCI). The development of the platinum– chromium (PtCr) alloy and Element™ stent architecture (or platform) is the result of more than eight years of research and development by Boston Scientific Corporation (BSC; Natick, MA, US) and builds on a pedigree… View more

Prevention & Chronic Conditions
EuroPCR 2021: Findings From the POEM Study
Author(s): Giulio G Stefanini Added: 2 years ago
Dr Giulio Stefanini (Humanitas Research Hospital, Milan, IT) discusses the findings from the multicentre POEM trial.The trial assessed the safety of the bioresorbable polymer-coated everolimus-eluting Synergy® stent in CAD patients undergoing PCI, followed by 1-month dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR). Questions: 1. What is the POEM Study and what does it… View more

Anticoagulation

Intervention
Author(s): Sidakpal Panaich , Theodore Schreiber , Cindy Grines Added: 3 years ago
Percutaneous coronary intervention (PCI) is one of the most commonly performed procedures in cardiology. More recently, the limitations of rigid metallic stents have led to the development of bioresorbable scaffolds (BRS). The earliest version of bioresorbable stent developed and tested in humans in 1990 was the Igaki-Tamai stent. It featured a thermal and balloon expandable stent that showed… View more

Imaging & Diagnostics
Second - versus First-generation Drug-eluting Stents
Author(s): Kamal Chitkara , Anthony H Gershlick Added: 3 years ago
First-generation Stents Since drug-eluting stents (DES) received the CE mark in 2002 and the US Food and Drug Administration (FDA) approved the first DES in 2003, there has been a significant increase in the use of these devices. The advent of DES has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Author(s): Roberto Diletti , Nicolas M Van Mieghem Added: 3 years ago
Since Andreas Gruentzig presented his pioneering work in 1977, 'three revolutions' in percutaneous coronary interventions (PCI) have characterised the field of interventional cardiology. Plain old balloon angioplasty (POBA) was refined by the introduction of bare metal stenting (BMS) (second revolution) to address the issue of acute vessel recoil and unacceptably high rates of restenosis. Drug… View more

Intervention
Author(s): Ehrin J Armstrong , Stephen W Waldo Added: 3 years ago
Patients with diabetes mellitus (DM) have an increased prevalence of coronary artery disease (CAD) and are more likely to require coronary revascularisation than patients without DM.1 Similar to the general population, CAD remains the most frequent cause of death among patients with DM.2 As the prevalence of DM continues to rise worldwide, the appropriate management and method of… View more

Prevention & Chronic Conditions

Intervention
ESC 2018: Results From the BIOSCIENCE Study
Author(s): Thomas Pilgrim Added: 5 years ago
Dr Thomas Pilgrim (University of Bern, CH) discusses BIOSCIENCE -Randomized comparison of an ultrathin cobaltchromium biodegradable polymer sirolimus-eluting stent with a thin strut durable polymer everolimus-eluting stent for PCI. Filmed by Radcliffe Cardiology on site at ESC 2018, Munich. View more

Prevention & Chronic Conditions
Author(s): Robert A Byrne , Eric Eeckhout , Gennaro Sardella , et al Added: 3 years ago
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established strategies for revascularisation in patients with coronary artery disease. While CABG was the standard of care for patients with multivessel disease, the introduction of baremetal stents (BMSs) and, later, drug-eluting stents (DESs) has led to an increased use of PCI in these more challenging cases… View more

Prevention & Chronic Conditions

Intervention
Author(s): Nicolaus Reifart , Mariann Gyöngyösi , Karl-Eugen Hauptmann , et al Added: 3 years ago
Coronary stent implantation is one of the most important developments in the field of percutaneous coronary revascularisation after the introduction of balloon angioplasty in 1977.1 The treatment of coronary artery disease (CAD) using a bare-metal stent (BMS) is considered effective; however, restenosis occurs in 15–35% of all cases, requiring repeated treatment.2–4 To overcome the restenosis… View more

Prevention & Chronic Conditions
EuroPCR 22: SYNERGY™ Non-inferior to BioMatrix NeoFlex in OCT SORT-OUT VIII
Author(s): Michael Mæng Added: 1 year ago
In this short interview, Dr Matthew Mæng (Aarhus University Hospital, DK) joins us to discuss the outcomes of a follow-up study on OCT SORT-OUT VIII (NCT02253108), originally presented at EuroPCR 2022. This follow-up study aimed to compare the outcomes of Boston Scientific's SYNERGY™ stent to the BioMatrix NeoFlex stent. Findings suggest that the SYNERGY™ stent was non-inferior to the BioMatrix… View more

Intervention